6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Cardiac B-OSE_Labeled_AE
Toxicities I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Acute B-OSE_Labeled_AE
Renal I-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Pulmonary B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Pulmonary B-OSE_Labeled_AE
Hypertension I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Dyspnea B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Venous B-OSE_Labeled_AE
Thrombosis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Infusion B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Hemorrhage B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Thrombocytopenia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Hepatic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
and O
Hepatic B-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
* O
Thrombotic B-OSE_Labeled_AE
Microangiopathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
* O
Posterior B-OSE_Labeled_AE
Reversible I-OSE_Labeled_AE
Encephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.14 O
) O
] O
* O
Increased O
Fatal B-NonOSE_AE
and O
Serious O
Toxicities O
in O
Combintaion O
with O
Melphalan O
and O
Prednisone O
in O
Newly O
Diagnosed O
Transplant-Ineligible O
Patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
occurring O
in O
at O
least O
20 O
% O
of O
patients O
treated O
with O
Kyprolis O
in O
monotherapy O
trials O
: O
anemia O
, O
fatigue O
, O
thrombocytopenia O
, O
nausea O
, O
pyrexia O
, O
dyspnea O
, O
diarrhea O
, O
headache O
, O
cough O
, O
edema O
peripheral O
. O

( O
6 O
) O
The O
most O
common O
adverse O
reactions O
occurring O
in O
at O
least O
20 O
% O
of O
patients O
treated O
with O
Kyprolis O
in O
the O
combination O
therapy O
trials O
: O
anemia O
, O
neutropenia O
, O
diarrhea O
, O
dyspnea O
, O
fatigue O
, O
thrombocytopenia O
, O
pyrexia O
, O
insomnia O
, O
muscle O
spasm O
, O
cough O
, O
upper O
respiratory O
tract O
infection O
, O
hypokalemia O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Amgen O
Medical O
Information O
at O
1-800-77-AMGEN O
( O
1-800-772-6436 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
, O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
medical O
practice O
. O

Safety O
Experience O
with O
Kyprolis O
in O
Combination O
with O
Lenalidomide O
and O
Dexamethasone O
in O
Patients O
with O
Multiple O
Myeloma O
The O
safety O
of O
Kyprolis O
in O
combination O
with O
lenalidomide O
and O
dexamethasone O
( O
KRd O
) O
was O
evaluated O
in O
an O
open-label O
randomized O
study O
in O
patients O
with O
relapsed O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
. O

Details O
of O
the O
study O
treatment O
are O
described O
in O
Section O
14.1 O
. O

The O
median O
number O
of O
cycles O
initiated O
was O
22 O
cycles O
for O
the O
KRd O
arm O
and O
14 O
cycles O
for O
the O
Rd O
arm O
. O

Deaths B-NonOSE_AE
due O
to O
adverse O
reactions O
within O
30 O
days O
of O
the O
last O
dose O
of O
any O
therapy O
in O
the O
KRd O
arm O
occurred O
in O
27/392 O
( O
7 O
% O
) O
patients O
compared O
with O
27/389 O
( O
7 O
% O
) O
patients O
who O
died B-NonOSE_AE
due O
to O
adverse O
events O
within O
30 O
days O
of O
the O
last O
dose O
of O
any O
Rd O
therapy O
. O

The O
most O
common O
cause O
of O
deaths B-NonOSE_AE
occurring O
in O
patients O
( O
% O
) O
in O
the O
two O
arms O
( O
KRd O
versus O
Rd O
) O
included O
cardiac B-NonOSE_AE
10 O
( O
3 O
% O
) O
versus O
7 O
( O
2 O
% O
) O
, O
infection B-NonOSE_AE
9 O
( O
2 O
% O
) O
versu O
s O
10 O
( O
3 O
% O
) O
, O
renal B-NonOSE_AE
0 O
( O
0 O
% O
) O
versus O
1 O
( O
< O
1 O
% O
) O
, O
and O
other O
adverse O
reactions O
9 O
( O
2 O
% O
) O
versus O
10 O
( O
3 O
% O
) O
. O

Serious O
adverse O
reactions O
were O
reported O
in O
60 O
% O
of O
the O
patients O
in O
the O
KRd O
arm O
and O
54 O
% O
of O
the O
patients O
in O
the O
Rd O
arm O
. O

The O
most O
common O
serious O
adverse O
reactions O
reported O
in O
the O
KRd O
arm O
as O
compared O
with O
the O
Rd O
arm O
were O
pneumonia B-OSE_Labeled_AE
( O
14 O
% O
versus O
11 O
% O
) O
, O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
4 O
% O
versus O
1.5 O
% O
) O
, O
pyrexia B-OSE_Labeled_AE
( O
4 O
% O
versus O
2 O
% O
) O
, O
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
3 O
% O
versus O
2 O
% O
) O
. O

Discontinuation O
due O
to O
any O
adverse O
reaction O
occurred O
in O
26 O
% O
in O
the O
KRd O
arm O
versus O
25 O
% O
in O
the O
Rd O
arm O
. O

Adverse O
reactions O
leading O
to O
discontinuation O
of O
Kyprolis O
occurred O
in O
12 O
% O
of O
patients O
and O
the O
most O
common O
reactions O
included O
pneumonia B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
( O
0.8 O
% O
) O
, O
and O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
0.8 O
% O
) O
. O

Common O
Adverse O
Reactions O
( O
> O
= O
10 O
% O
) O
The O
adverse O
reactions O
in O
the O
first O
12 O
cycles O
of O
therapy O
that O
occurred O
at O
a O
rate O
of O
10 O
% O
or O
greater O
in O
the O
KRd O
arm O
are O
presented O
in O
Table O
8 O
. O

Table O
8 O
: O
Most O
Common O
Adverse O
Reactions O
( O
> O
= O
10 O
% O
in O
the O
KRd O
Arm O
) O
Occurring O
in O
Cycles O
1-12 O
( O
20/27 O
mg/m2 O
Regimen O
In O
Combination O
with O
Lenalidomide O
and O
Dexamethasone O
) O
KRd O
Arm O
( O
N O
= O
392 O
) O
n O
( O
% O
) O
Rd O
Arm O
( O
N O
= O
389 O
) O
n O
( O
% O
) O
Adverse O
Reactions O
by O
Body O
System O
Any O
Grade O
> O
= O
Grade O
3 O
Any O
Grade O
> O
= O
Grade O
3 O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Anemia B-OSE_Labeled_AE
138 O
( O
35 O
) O
53 O
( O
14 O
) O
127 O
( O
33 O
) O
47 O
( O
12 O
) O
Neutropenia B-OSE_Labeled_AE
124 O
( O
32 O
) O
104 O
( O
27 O
) O
115 O
( O
30 O
) O
89 O
( O
23 O
) O
Thrombocytopenia B-OSE_Labeled_AE
100 O
( O
26 O
) O
58 O
( O
15 O
) O
75 O
( O
19 O
) O
39 O
( O
10 O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
115 O
( O
29 O
) O
7 O
( O
2 O
) O
105 O
( O
27 O
) O
12 O
( O
3 O
) O
Constipation B-OSE_Labeled_AE
68 O
( O
17 O
) O
0 O
53 O
( O
14 O
) O
1 O
( O
0 O
) O
Nausea B-OSE_Labeled_AE
60 O
( O
15 O
) O
1 O
( O
0 O
) O
39 O
( O
10 O
) O
3 O
( O
1 O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
109 O
( O
28 O
) O
21 O
( O
5 O
) O
104 O
( O
27 O
) O
20 O
( O
5 O
) O
Pyrexia B-OSE_Labeled_AE
93 O
( O
24 O
) O
5 O
( O
1 O
) O
64 O
( O
17 O
) O
1 O
( O
0 O
) O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
63 O
( O
16 O
) O
2 O
( O
1 O
) O
57 O
( O
15 O
) O
2 O
( O
1 O
) O
Asthenia B-OSE_Labeled_AE
53 O
( O
14 O
) O
11 O
( O
3 O
) O
46 O
( O
12 O
) O
7 O
( O
2 O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
85 O
( O
22 O
) O
7 O
( O
2 O
) O
52 O
( O
13 O
) O
3 O
( O
1 O
) O
Nasopharyngitis B-OSE_Labeled_AE
63 O
( O
16 O
) O
0 O
43 O
( O
11 O
) O
0 O
Bronchitis B-OSE_Labeled_AE
54 O
( O
14 O
) O
5 O
( O
1 O
) O
39 O
( O
10 O
) O
2 O
( O
1 O
) O
Pneumonia B-OSE_Labeled_AE
a O
54 O
( O
14 O
) O
35 O
( O
9 O
) O
43 O
( O
11 O
) O
27 O
( O
7 O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Hypokalemia B-OSE_Labeled_AE
78 O
( O
20 O
) O
22 O
( O
6 O
) O
35 O
( O
9 O
) O
12 O
( O
3 O
) O
Hypocalcemia B-OSE_Labeled_AE
55 O
( O
14 O
) O
10 O
( O
3 O
) O
39 O
( O
10 O
) O
5 O
( O
1 O
) O
Hyperglycemia B-OSE_Labeled_AE
43 O
( O
11 O
) O
18 O
( O
5 O
) O
33 O
( O
9 O
) O
15 O
( O
4 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
88 O
( O
22 O
) O
3 O
( O
1 O
) O
73 O
( O
19 O
) O
3 O
( O
1 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
b O
43 O
( O
11 O
) O
7 O
( O
2 O
) O
37 O
( O
10 O
) O
4 O
( O
1 O
) O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
63 O
( O
16 O
) O
6 O
( O
2 O
) O
50 O
( O
13 O
) O
8 O
( O
2 O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
c O
91 O
( O
23 O
) O
2 O
( O
1 O
) O
52 O
( O
13 O
) O
0 O
Dyspnea B-OSE_Labeled_AE
d O
70 O
( O
18 O
) O
9 O
( O
2 O
) O
58 O
( O
15 O
) O
6 O
( O
2 O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
45 O
( O
12 O
) O
5 O
( O
1 O
) O
53 O
( O
14 O
) O
5 O
( O
1 O
) O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Embolic B-OSE_Labeled_AE
and O
thrombotic O
events I-OSE_Labeled_AE
venous I-OSE_Labeled_AE
e O
49 O
( O
13 O
) O
16 O
( O
4 O
) O
22 O
( O
6 O
) O
9 O
( O
2 O
) O
Hypertension B-OSE_Labeled_AE
f O
41 O
( O
11 O
) O
12 O
( O
3 O
) O
15 O
( O
4 O
) O
4 O
( O
1 O
) O
KRd O
= O
Kyprolis O
, O
lenalidomide O
, O
and O
dexamethasone O
; O
Rd O
= O
lenalidomide O
and O
dexamethasone O
a O
Pneumonia B-OSE_Labeled_AE
includes O
pneumonia B-OSE_Labeled_AE
and O
bronchopneumonia B-OSE_Labeled_AE
. O

b O
Peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
includes O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
motor I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

c O
Cough B-OSE_Labeled_AE
includes O
cough B-OSE_Labeled_AE
and O
productive B-OSE_Labeled_AE
cough I-OSE_Labeled_AE
. O

d O
Dyspnea B-OSE_Labeled_AE
includes O
dyspnea B-OSE_Labeled_AE
and O
dyspnea B-OSE_Labeled_AE
exertional I-OSE_Labeled_AE
. O

e O
Embolic B-OSE_Labeled_AE
and O
thrombotic O
events I-OSE_Labeled_AE
, O
venous I-OSE_Labeled_AE
include O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
superficial I-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
limb I-OSE_Labeled_AE
, O
post B-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
. O

f O
Hypertension B-OSE_Labeled_AE
includes O
hypertension B-OSE_Labeled_AE
, O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
. O

There O
were O
274 O
( O
70 O
% O
) O
patients O
in O
the O
KRd O
arm O
who O
received O
treatment O
beyond O
Cycle O
12 O
. O

There O
were O
no O
new O
clinically O
relevant O
adverse O
reactions O
that O
emerged O
in O
the O
later O
treatment O
cycles O
. O

Adverse O
Reactions O
Occurring O
at O
a O
Frequency O
of O
< O
10 O
% O
* O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
* O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
congestive I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
* O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
cataract B-OSE_Labeled_AE
, O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
* O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
toothache B-OSE_Labeled_AE
* O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
chills B-OSE_Labeled_AE
, O
infusion B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
multi B-OSE_Labeled_AE
- I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
* O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
: O
influenza B-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
* O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
: O
dehydration B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypoalbuminemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
* O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
muscular B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
hypoesthesia B-OSE_Labeled_AE
, O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
deafness B-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
anxiety B-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
* O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
acute I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
* O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
dysphonia B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
erythema B-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
* O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
Grade O
3 O
and O
higher O
adverse O
reactions O
that O
occurred O
during O
Cycles O
1-12 O
with O
a O
substantial O
difference O
( O
> O
= O
2 O
% O
) O
between O
the O
two O
arms O
were O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
and O
hypophosphatemia B-OSE_Labeled_AE
. O

Laboratory O
Abnormalities O
Table O
9 O
describes O
Grade O
3-4 O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
reported O
at O
a O
rate O
of O
> O
= O
10 O
% O
in O
the O
KRd O
arm O
for O
patients O
who O
received O
combination O
therapy O
. O

Table O
9 O
: O
Grade O
3-4 O
Laboratory O
Abnormalities O
( O
> O
= O
10 O
% O
in O
the O
KRd O
Arm O
) O
in O
Cycles O
1-12 O
( O
20/27 O
mg/m2 O
Regimen O
In O
Combination O
with O
Lenalidomide O
and O
Dexamethasone O
) O
Laboratory B-NonOSE_AE
Abnormality I-NonOSE_AE
KRd O
( O
N O
= O
392 O
) O
n O
( O
% O
) O
Rd O
( O
N O
= O
389 O
) O
n O
( O
% O
) O
Decreased B-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
182 O
( O
46 O
) O
119 O
( O
31 O
) O
Decreased B-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
neutrophil I-OSE_Labeled_AE
count I-OSE_Labeled_AE
152 O
( O
39 O
) O
140 O
( O
36 O
) O
Decreased B-OSE_Labeled_AE
phosphorus I-OSE_Labeled_AE
122 O
( O
31 O
) O
106 O
( O
27 O
) O
Decreased B-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
101 O
( O
26 O
) O
59 O
( O
15 O
) O
Decreased B-OSE_Labeled_AE
total I-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
97 O
( O
25 O
) O
71 O
( O
18 O
) O
Decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
58 O
( O
15 O
) O
68 O
( O
18 O
) O
Decreased B-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
41 O
( O
11 O
) O
23 O
( O
6 O
) O
KRd O
= O
Kyprolis O
, O
lenalidomide O
, O
and O
dexamethasone O
; O
Rd O
= O
lenalidomide O
and O
dexamethasone O
Safety O
Experience O
with O
Kyprolis O
in O
Combination O
with O
Dexamethasone O
in O
Patients O
with O
Multiple O
Myeloma O
The O
safety O
of O
Kyprolis O
in O
combination O
with O
dexamethasone O
was O
evaluated O
in O
an O
open-label O
, O
randomized O
trial O
of O
patients O
with O
relapsed O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
. O

The O
study O
treatment O
is O
described O
in O
Section O
14.2 O
. O

Patients O
received O
treatment O
for O
a O
median O
duration O
of O
40 O
weeks O
in O
the O
Kyprolis/dexamethasone O
( O
Kd O
) O
arm O
and O
27 O
weeks O
in O
the O
bortezomib/dexamethasone O
( O
Vd O
) O
arm O
. O

Deaths B-NonOSE_AE
due O
to O
adverse O
reactions O
within O
30 O
days O
of O
last O
study O
treatment O
occurred O
in O
22/463 O
( O
5 O
% O
) O
patients O
in O
the O
Kd O
arm O
and O
21/456 O
( O
5 O
% O
) O
patients O
in O
the O
Vd O
arm O
. O

The O
causes O
of O
death B-NonOSE_AE
occurring O
in O
patients O
( O
% O
) O
in O
the O
two O
arms O
( O
Kd O
versus O
Vd O
) O
included O
cardiac B-NonOSE_AE
7 O
( O
2 O
% O
) O
versus O
5 O
( O
1 O
% O
) O
, O
infections B-NonOSE_AE
5 O
( O
1 O
% O
) O
versus O
8 O
( O
2 O
% O
) O
, O
disease O
progression O
6 O
( O
1 O
% O
) O
versus O
4 O
( O
1 O
% O
) O
, O
pulmonary B-NonOSE_AE
3 O
( O
1 O
% O
) O
versus O
2 O
( O
< O
1 O
% O
) O
, O
renal B-NonOSE_AE
1 O
( O
< O
1 O
% O
) O
versus O
0 O
( O
0 O
% O
) O
, O
and O
other O
adverse O
events O
2 O
( O
< O
1 O
% O
) O
versus O
2 O
( O
< O
1 O
% O
) O
. O

Serious O
adverse O
reactions O
were O
reported O
in O
48 O
% O
of O
the O
patients O
in O
the O
Kd O
arm O
and O
36 O
% O
of O
the O
patients O
in O
the O
Vd O
arm O
. O

In O
both O
treatment O
arms O
, O
pneumonia B-OSE_Labeled_AE
was O
the O
most O
commonly O
reported O
serious O
adverse O
reaction O
( O
6 O
% O
versus O
9 O
% O
) O
. O

Discontinuation O
due O
to O
any O
adverse O
reaction O
occurred O
in O
20 O
% O
in O
the O
Kd O
arm O
versus O
21 O
% O
in O
the O
Vd O
arm O
. O

The O
most O
common O
reaction O
leading O
to O
discontinuation O
was O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
the O
Kd O
arm O
( O
n O
= O
6 O
, O
1.3 O
% O
) O
and O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
in O
the O
Vd O
arm O
( O
n O
= O
19 O
, O
4.2 O
% O
) O
. O

Common O
Adverse O
Reactions O
( O
> O
= O
10 O
% O
) O
Adverse O
reactions O
in O
the O
first O
6 O
months O
of O
therapy O
that O
occurred O
at O
a O
rate O
of O
10 O
% O
or O
greater O
in O
the O
Kd O
arm O
are O
presented O
in O
Table O
10 O
. O

Table O
10 O
: O
Most O
Common O
Adverse O
Reactions O
( O
> O
= O
10 O
% O
in O
the O
Kd O
Arm O
) O
Occurring O
in O
Months O
1-6 O
( O
20/56 O
mg/m2 O
Regimen O
In O
Combination O
with O
Dexamethasone O
) O
Kd O
( O
N O
= O
463 O
) O
n O
( O
% O
) O
Vd O
( O
N O
= O
456 O
) O
n O
( O
% O
) O
Adverse O
Reaction O
by O
Body O
System O
Any O
Grade O
> O
= O
Grade O
3 O
Any O
Grade O
> O
= O
Grade O
3 O
Blood B-NonOSE_AE
and I-NonOSE_AE
L I-NonOSE_AE
ymphatic I-NonOSE_AE
S I-NonOSE_AE
ystem I-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
Anemia B-OSE_Labeled_AE
160 O
( O
35 O
) O
57 O
( O
12 O
) O
112 O
( O
25 O
) O
43 O
( O
9 O
) O
Thrombocytopenia B-OSE_Labeled_AE
a O
127 O
( O
27 O
) O
46 O
( O
10 O
) O
112 O
( O
25 O
) O
65 O
( O
14 O
) O
Gastrointestinal B-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
111 O
( O
24 O
) O
14 O
( O
3 O
) O
150 O
( O
33 O
) O
26 O
( O
6 O
) O
Nausea B-OSE_Labeled_AE
69 O
( O
15 O
) O
4 O
( O
1 O
) O
66 O
( O
15 O
) O
3 O
( O
1 O
) O
Constipation B-OSE_Labeled_AE
58 O
( O
13 O
) O
1 O
( O
0 O
) O
109 O
( O
24 O
) O
6 O
( O
1 O
) O
Vomiting B-OSE_Labeled_AE
45 O
( O
10 O
) O
5 O
( O
1 O
) O
32 O
( O
7 O
) O
3 O
( O
1 O
) O
General B-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
and I-NonOSE_AE
A I-NonOSE_AE
dministration I-NonOSE_AE
S I-NonOSE_AE
ite I-NonOSE_AE
C I-NonOSE_AE
onditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
112 O
( O
24 O
) O
13 O
( O
3 O
) O
124 O
( O
27 O
) O
25 O
( O
6 O
) O
Pyrexia B-OSE_Labeled_AE
102 O
( O
22 O
) O
9 O
( O
2 O
) O
52 O
( O
11 O
) O
3 O
( O
1 O
) O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
75 O
( O
16 O
) O
3 O
( O
1 O
) O
73 O
( O
16 O
) O
3 O
( O
1 O
) O
Asthenia B-OSE_Labeled_AE
71 O
( O
15 O
) O
9 O
( O
2 O
) O
66 O
( O
14 O
) O
13 O
( O
3 O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
I I-NonOSE_AE
nfestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
66 O
( O
14 O
) O
4 O
( O
1 O
) O
54 O
( O
12 O
) O
3 O
( O
1 O
) O
Bronchitis B-OSE_Labeled_AE
54 O
( O
12 O
) O
5 O
( O
1 O
) O
26 O
( O
6 O
) O
2 O
( O
0 O
) O
Nasopharyngitis B-OSE_Labeled_AE
45 O
( O
10 O
) O
0 O
( O
0 O
) O
42 O
( O
9 O
) O
1 O
( O
0 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
C I-NonOSE_AE
onnective I-NonOSE_AE
T I-NonOSE_AE
issue I-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
66 O
( O
14 O
) O
1 O
( O
0 O
) O
22 O
( O
5 O
) O
3 O
( O
1 O
) O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
58 O
( O
13 O
) O
7 O
( O
2 O
) O
60 O
( O
13 O
) O
8 O
( O
2 O
) O
Nervous B-NonOSE_AE
S I-NonOSE_AE
ystem I-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
68 O
( O
15 O
) O
4 O
( O
1 O
) O
38 O
( O
8 O
) O
2 O
( O
0 O
) O
Peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
b O
, O
c O
54 O
( O
12 O
) O
7 O
( O
2 O
) O
167 O
( O
37 O
) O
23 O
( O
5 O
) O
Psychiatric B-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
103 O
( O
22 O
) O
5 O
( O
1 O
) O
113 O
( O
25 O
) O
10 O
( O
2 O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
T I-NonOSE_AE
horacic I-NonOSE_AE
and I-NonOSE_AE
M I-NonOSE_AE
ediastinal I-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
d O
123 O
( O
27 O
) O
23 O
( O
5 O
) O
66 O
( O
15 O
) O
8 O
( O
2 O
) O
Cough B-OSE_Labeled_AE
e O
91 O
( O
20 O
) O
0 O
( O
0 O
) O
61 O
( O
13 O
) O
2 O
( O
0 O
) O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
f O
80 O
( O
17 O
) O
29 O
( O
6 O
) O
33 O
( O
7 O
) O
12 O
( O
3 O
) O
Kd O
= O
Kyprolis O
and O
dexamethasone O
; O
Vd O
= O
bortezomib O
and O
dexamethasone O
a O
Thrombocytopenia B-OSE_Labeled_AE
includes O
platelet B-OSE_Labeled_AE
count I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
and O
thrombocytopenia B-OSE_Labeled_AE
. O

b O
Peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
include O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
motor I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

c O
See O
Clinical O
Studies O
( O
14.2 O
) O
. O

d O
Dyspnea B-OSE_Labeled_AE
includes O
dyspnea B-OSE_Labeled_AE
and O
dyspnea B-OSE_Labeled_AE
exertional I-OSE_Labeled_AE
. O

e O
Cough B-OSE_Labeled_AE
includes O
cough B-OSE_Labeled_AE
and O
productive B-OSE_Labeled_AE
cough I-OSE_Labeled_AE
. O

f O
Hypertension B-OSE_Labeled_AE
includes O
hypertension B-OSE_Labeled_AE
, O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
and O
hypertensive B-OSE_Labeled_AE
emergency I-OSE_Labeled_AE
. O

The O
event O
rate O
of O
> O
= O
Grade O
2 O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
in O
the O
Kd O
arm O
was O
6 O
% O
( O
95 O
% O
CI O
: O
4 O
, O
8 O
) O
versus O
32 O
% O
( O
95 O
% O
CI O
: O
28 O
, O
36 O
) O
in O
the O
Vd O
arm O
. O

Adverse O
Reactions O
Occurring O
at O
a O
Frequency O
of O
< O
10 O
% O
* O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
, O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
* O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
congestive I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
palpitations B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
* O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
cataract B-OSE_Labeled_AE
, O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
* O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
toothache B-OSE_Labeled_AE
* O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
infusion B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
inflammation B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
and O
erythema B-OSE_Labeled_AE
) O
, O
pain B-OSE_Labeled_AE
* O
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
cholestasis B-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
hyperbilirubinemia B-OSE_Labeled_AE
* O
Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
drug B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
* O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
: O
bronchopneumonia B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
* O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
: O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
hypercalcemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypoalbuminemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
* O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
muscular B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
chest I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
anxiety B-OSE_Labeled_AE
* O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
acute I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
* O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
distress I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
dysphonia B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
wheezing B-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
erythema B-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
* O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
Laboratory O
Abnormalities O
Table O
11 O
describes O
Grades O
3-4 O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
reported O
at O
a O
rate O
of O
> O
= O
10 O
% O
in O
the O
Kd O
arm O
. O

Table O
11 O
: O
Grades O
3-4 O
Laboratory O
Abnormalities O
( O
> O
= O
10 O
% O
) O
in O
Months O
1-6 O
( O
20/56 O
mg/m2 O
Regimen O
In O
Combination O
with O
Dexamethasone O
) O
Laboratory B-NonOSE_AE
Abnormality I-NonOSE_AE
Kd O
( O
N O
= O
463 O
) O
n O
( O
% O
) O
Vd O
( O
N O
= O
456 O
) O
n O
( O
% O
) O
Decreased B-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
248 O
( O
54 O
) O
180 O
( O
40 O
) O
Increase B-OSE_Labeled_AE
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
243 O
( O
53 O
) O
198 O
( O
43 O
) O
Decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
79 O
( O
17 O
) O
68 O
( O
15 O
) O
Decreased B-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
85 O
( O
18 O
) O
77 O
( O
17 O
) O
Decreased B-OSE_Labeled_AE
phosphorus I-OSE_Labeled_AE
73 O
( O
16 O
) O
61 O
( O
13 O
) O
Decreased B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
clearance I-OSE_Labeled_AE
a O
65 O
( O
14 O
) O
49 O
( O
11 O
) O
Increased B-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
55 O
( O
12 O
) O
21 O
( O
5 O
) O
Kd O
= O
Kyprolis O
and O
dexamethasone O
; O
Vd O
= O
bortezomib O
and O
dexamethasone O
a O
Calculated O
using O
the O
Cockcroft-Gault O
formula O
. O

Safety O
Experience O
with O
Kyprolis O
in O
Patients O
with O
Multiple O
Myeloma O
who O
Received O
Monotherapy O
The O
safety O
of O
Kyprolis O
, O
dosed O
at O
20/27 O
mg/m O
2 O
by O
up O
to O
10-minute O
infusion O
, O
was O
evaluated O
in O
clinical O
trials O
in O
which O
598 O
patients O
with O
relapsed O
and/or O
refractory O
myeloma B-Not_AE_Candidate
received O
Kyprolis O
monotherapy O
starting O
with O
the O
20 O
mg/m O
2 O
dose O
in O
Cycle O
1 O
, O
Day O
1 O
and O
escalating O
to O
27 O
mg/m O
2 O
on O
Cycle O
1 O
, O
Day O
8 O
or O
Cycle O
2 O
, O
Day O
1 O
. O

Premedication O
with O
dexamethasone O
4 O
mg O
was O
required O
before O
each O
dose O
in O
Cycle O
1 O
and O
was O
optional O
for O
subsequent O
cycles O
. O

The O
median O
age O
was O
64 O
years O
( O
range O
32-87 O
) O
, O
and O
approximately O
57 O
% O
were O
male O
. O

The O
patients O
received O
a O
median O
of O
5 O
( O
range O
1-20 O
) O
prior O
regimens O
. O

The O
median O
number O
of O
cycles O
initiated O
was O
4 O
( O
range O
1-35 O
) O
. O

Serious O
adverse O
reactions O
, O
regardless O
of O
causality O
, O
were O
reported O
in O
50 O
% O
of O
patients O
in O
the O
pooled O
Kyprolis O
monotherapy O
studies O
( O
N O
= O
598 O
) O
. O

The O
most O
common O
serious O
adverse O
reactions O
were O
: O
pneumonia B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
disease B-OSE_Labeled_AE
progression I-OSE_Labeled_AE
( O
4 O
% O
) O
, O
pyrexia B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
hypercalcemia B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
multiple B-OSE_Labeled_AE
myeloma I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
anemia B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
and O
dyspnea B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

In O
patients O
treated O
with O
Kyprolis O
, O
the O
incidence O
of O
serious O
adverse O
reactions O
was O
higher O
in O
those O
> O
= O
65 O
years O
old O
and O
those O
> O
= O
75 O
years O
old O
[ O
see O
Geriatric O
Use O
( O
8.5 O
) O
] O
. O

Deaths B-NonOSE_AE
due O
to O
adverse O
reactions O
within O
30 O
days O
of O
the O
last O
dose O
of O
Kyprolis O
occurred O
in O
30/598 O
( O
5 O
% O
) O
patients O
receiving O
Kyprolis O
monotherapy O
. O

These O
adverse O
reactions O
were O
related O
to O
cardiac B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
in O
10 O
( O
2 O
% O
) O
patients O
, O
infections B-OSE_Labeled_AE
in O
8 O
( O
1 O
% O
) O
patients O
, O
renal B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
in O
4 O
( O
< O
1 O
% O
) O
patients O
, O
and O
other O
adverse O
reactions O
in O
8 O
( O
1 O
% O
) O
patients O
. O

In O
a O
randomized O
trial O
comparing O
Kyprolis O
as O
a O
single O
agent O
versus O
corticosteroids O
with O
optional O
oral O
cyclophosphamide O
for O
patients O
with O
relapsed O
and O
refractory O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
, O
mortality B-NonOSE_AE
was O
higher O
in O
the O
patients O
treated O
with O
Kyprolis O
in O
comparison O
to O
the O
control O
arm O
in O
the O
subgroup O
of O
48 O
patients O
> O
= O
75 O
years O
of O
age O
. O

The O
most O
common O
cause O
of O
discontinuation O
due O
to O
an O
adverse O
reaction O
was O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
2 O
% O
) O
. O

Safety O
of O
Kyprolis O
monotherapy O
dosed O
at O
20/56 O
mg/m O
2 O
by O
30-minute O
infusion O
was O
evaluated O
in O
a O
multicenter O
, O
open-label O
study O
in O
patients O
with O
relapsed O
and/or O
refractory O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
. O

The O
study O
treatment O
is O
described O
in O
Section O
14.3 O
. O

The O
patients O
received O
a O
median O
of O
4 O
( O
range O
1-10 O
) O
prior O
regimens O
. O

The O
common O
adverse O
reactions O
occurring O
at O
a O
rate O
of O
20 O
% O
or O
greater O
with O
Kyprolis O
monotherapy O
are O
presented O
in O
Table O
12 O
. O

Table O
12 O
: O
Most O
Common O
Adverse O
Reactions O
( O
> O
= O
20 O
% O
) O
with O
Kyprolis O
Monotherapy O
20/56 O
mg/m O
2 O
by O
30 O
- O
minute O
infusion O
( O
N O
= O
24 O
) O
20/27 O
mg/m O
2 O
by O
2 O
- O
to O
10 O
- O
minute O
infusion O
( O
N O
= O
598 O
) O
Adverse O
Reaction O
Any O
Grade O
n O
( O
% O
) O
Grades O
3 O
- O
5 O
n O
( O
% O
) O
Any O
Grade O
n O
( O
% O
) O
Grades O
3 O
- O
5 O
n O
( O
% O
) O
Fatigue B-OSE_Labeled_AE
14 O
( O
58 O
) O
2 O
( O
8 O
) O
238 O
( O
40 O
) O
25 O
( O
4 O
) O
Dyspnea B-OSE_Labeled_AE
a O
14 O
( O
58 O
) O
2 O
( O
8 O
) O
202 O
( O
34 O
) O
21 O
( O
4 O
) O
Pyrexia B-OSE_Labeled_AE
14 O
( O
58 O
) O
0 O
177 O
( O
30 O
) O
11 O
( O
2 O
) O
Thrombocytopenia B-OSE_Labeled_AE
13 O
( O
54 O
) O
13 O
( O
54 O
) O
220 O
( O
37 O
) O
152 O
( O
25 O
) O
Nausea B-OSE_Labeled_AE
13 O
( O
54 O
) O
0 O
211 O
( O
35 O
) O
7 O
( O
1 O
) O
Anemia B-OSE_Labeled_AE
10 O
( O
42 O
) O
7 O
( O
29 O
) O
291 O
( O
49 O
) O
141 O
( O
24 O
) O
Hypertension B-OSE_Labeled_AE
b O
10 O
( O
42 O
) O
3 O
( O
13 O
) O
90 O
( O
15 O
) O
22 O
( O
4 O
) O
Chills B-OSE_Labeled_AE
9 O
( O
38 O
) O
0 O
73 O
( O
12 O
) O
1 O
( O
< O
1 O
) O
Headache B-OSE_Labeled_AE
8 O
( O
33 O
) O
0 O
141 O
( O
24 O
) O
7 O
( O
1 O
) O
Cough B-OSE_Labeled_AE
c O
8 O
( O
33 O
) O
0 O
134 O
( O
22 O
) O
2 O
( O
< O
1 O
) O
Vomiting B-OSE_Labeled_AE
8 O
( O
33 O
) O
0 O
104 O
( O
17 O
) O
4 O
( O
1 O
) O
Lymphopenia B-OSE_Labeled_AE
8 O
( O
33 O
) O
8 O
( O
33 O
) O
85 O
( O
14 O
) O
73 O
( O
12 O
) O
Insomnia B-OSE_Labeled_AE
7 O
( O
29 O
) O
0 O
75 O
( O
13 O
) O
0 O
Dizziness B-OSE_Labeled_AE
7 O
( O
29 O
) O
0 O
64 O
( O
11 O
) O
5 O
( O
1 O
) O
Diarrhea B-OSE_Labeled_AE
6 O
( O
25 O
) O
1 O
( O
4 O
) O
160 O
( O
27 O
) O
8 O
( O
1 O
) O
Blood B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
6 O
( O
25 O
) O
1 O
( O
4 O
) O
103 O
( O
17 O
) O
15 O
( O
3 O
) O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
5 O
( O
21 O
) O
0 O
118 O
( O
20 O
) O
1 O
( O
< O
1 O
) O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
5 O
( O
21 O
) O
1 O
( O
4 O
) O
115 O
( O
19 O
) O
19 O
( O
3 O
) O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
5 O
( O
21 O
) O
1 O
( O
4 O
) O
112 O
( O
19 O
) O
15 O
( O
3 O
) O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
5 O
( O
21 O
) O
0 O
89 O
( O
15 O
) O
2 O
( O
< O
1 O
) O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
5 O
( O
21 O
) O
0 O
62 O
( O
10 O
) O
2 O
( O
< O
1 O
) O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
5 O
( O
21 O
) O
0 O
20 O
( O
3 O
) O
1 O
( O
< O
1 O
) O
a O
Dyspnea B-OSE_Labeled_AE
includes O
preferred O
terms O
of O
dyspnea B-OSE_Labeled_AE
and O
dyspnea B-OSE_Labeled_AE
exertional I-OSE_Labeled_AE
. O

b O
Hypertension B-OSE_Labeled_AE
includes O
hypertension B-OSE_Labeled_AE
, O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
and O
hypertensive B-OSE_Labeled_AE
emergency I-OSE_Labeled_AE
. O

c O
Cough B-OSE_Labeled_AE
includes O
cough B-OSE_Labeled_AE
and O
productive B-OSE_Labeled_AE
cough I-OSE_Labeled_AE
. O

Adverse O
Reactions O
Occurring O
at O
a O
Frequency O
of O
< O
20 O
% O
* O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
* O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
congestive I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
* O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
cataract B-OSE_Labeled_AE
, O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
* O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
toothache B-OSE_Labeled_AE
* O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
asthenia B-OSE_Labeled_AE
, O
infusion B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
multi B-OSE_Labeled_AE
- I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
* O
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
* O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
: O
bronchitis B-OSE_Labeled_AE
, O
bronchopneumonia B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
* O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
: O
hypercalcemia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypoalbuminemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
* O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
arthralgia B-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
chest I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
hypoesthesia B-OSE_Labeled_AE
, O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
motor I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
anxiety B-OSE_Labeled_AE
* O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
* O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
dysphonia B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
erythema B-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
* O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
embolic B-OSE_Labeled_AE
and O
thrombotic O
events I-OSE_Labeled_AE
, O
venous I-OSE_Labeled_AE
( O
including O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
) O
, O
hemorrhage B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
Grade O
3 O
and O
higher O
adverse O
reactions O
occurring O
at O
an O
incidence O
of O
> O
1 O
% O
include O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
congestive I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypoalbuminemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
acute I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
and O
hypotension B-OSE_Labeled_AE
. O

Laboratory O
Abnormalities O
Table O
13 O
describes O
Grade O
3-4 O
laboratory O
abnormalities O
reported O
at O
a O
rate O
of O
> O
10 O
% O
for O
patients O
who O
received O
Kyprolis O
monotherapy O
. O

Table O
13 O
: O
Grade O
3-4 O
Laboratory O
Abnormalities O
( O
> O
10 O
% O
) O
with O
Kyprolis O
Monotherapy O
Laboratory B-NonOSE_AE
Abnormality I-NonOSE_AE
Kyprolis O
20/56 O
mg/m O
2 O
( O
N O
= O
24 O
) O
Kyprolis O
20/27 O
mg/m O
2 O
( O
N O
= O
598 O
) O
Decreased B-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
15 O
( O
63 O
) O
151 O
( O
25 O
) O
Decreased B-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
11 O
( O
46 O
) O
184 O
( O
31 O
) O
Decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
7 O
( O
29 O
) O
132 O
( O
22 O
) O
Decreased B-OSE_Labeled_AE
total I-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
3 O
( O
13 O
) O
71 O
( O
12 O
) O
Decreased B-OSE_Labeled_AE
sodium I-OSE_Labeled_AE
2 O
( O
8 O
) O
69 O
( O
12 O
) O
Decreased B-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
neutrophil I-OSE_Labeled_AE
count I-OSE_Labeled_AE
2 O
( O
8 O
) O
67 O
( O
11 O
) O
6.2 O
Postmarketing O
Experience O
The O
following O
additional O
adverse O
reactions O
were O
reported O
in O
the O
postmarketing O
experience O
with O
Kyprolis O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
: O
hemolytic B-OSE_Labeled_AE
uremic I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HUS I-OSE_Labeled_AE
) O
, O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
pericarditis B-OSE_Labeled_AE
. O

